Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial (DREAM-PRIDE)
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)
Sponsor: Beijing Tiantan Hospital
This NA trial investigates Drug Eluting Stents (DES) and Drug-eluting Stent and is currently actively recruiting participants. Beijing Tiantan Hospital leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Jan 2025 — Present [monthly]
Recruiting NA
-
Nov 2024 — Jan 2025 [monthly]
Recruiting NA
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Feb 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Dec 2022 — Feb 2024 [monthly]
Recruiting NA
-
Sep 2021 — Dec 2022 [monthly]
Recruiting NA
First recorded
Jul 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Tiantan Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Beijing, China , Benxi, China , Cangzhou, China , Changchun, China , Hangzhou, China , Hohhot, China , Lishui, China , Nanjing, China , Ningbo, China and 6 more locations